Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesTransglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer
Journal of Cancer Research & Clinical Oncology, 09/25/09
Park K-S et al. – Good responders of cisplatin in NSCLC could be identified by the promoter methylation of TGM2 and that TGase 2 inhibition appears to be an effective cisplatin-sensitizing modality in NSCLC.
Methods- TGM2 promoter methylation was analyzed by sodium bisulfite sequencing
- Cisplatin sensitivity was analyzed by treatment of cisplatin in NSCLC cell lines with/without TGM2 or TGM2 siRNA transfection
- In one-third of NSCLC cell lines, TGase 2 gene (TGM2) was silenced by promoter methylation
- The TGM2 promoter-methylated cell lines (HCC-95 and HCC-1588) showed relatively higher sensitivity to cisplatin than the TGM2-expressing cell lines (NCI-H1299 and HCC-1195)
- Down-regulation and over-expression of TGM2 in those NSCLC cells also suggested a positive correlation of cisplatin sensitivity and TGM2 inhibition. With doxorubicin, the relationship was quite similar
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer
Oncogene, 12/09/09
Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy
Anti-Cancer Drugs, 12/09/09
EphA2 in the Early Pathogenesis and Progression of Non–Small Cell Lung Cancer
Cancer Prevention Research, 12/09/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases
Clinical Cancer Research, 12/09/09
A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy
Breast Cancer Research and Treatment, 12/09/09
A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women
Breast Cancer Research and Treatment, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor